Literature DB >> 15465801

Ornithine alpha-ketoglutarate as a potent precursor of arginine and nitric oxide: a new job for an old friend.

Luc Cynober1.   

Abstract

Ornithine alpha-ketoglutarate (OKG) is a salt formed of 2 molecules of ornithine and 1 alpha-ketoglutarate. Its administration improves nutritional status in chronically malnourished (e.g., elderly) and acutely malnourished patients (especially burn and trauma patients). There is evidence that OKG activity is not the simple addition of the effects of ornithine (Orn) and alpha-ketoglutarate (alphaKG), because the presence of both moieties is required to induce the generation of key metabolites such as glutamine, proline, and arginine (Arg), whereas this does not occur when one or the other is given separately. This observation is related to the fact that the main feature of Orn at the whole-body level is to be metabolized through the Orn aminotransferase-dependent pathway, whereas the simultaneous administration of Orn and alphaKG saturates this pathway, diverting Orn toward metabolism into Arg. For years, OKG activity has been associated with its ability to induce the secretion of anabolic hormones, such as insulin and growth hormone, and to increase glutamine and polyamine synthesis. Recent studies using chemical inhibitors of nitric oxide synthase (NOS) suggest that nitric oxide derived from Arg could be partly involved in OKG activity. The use of genetically modified animals (i.e., knockout for NOS expression) is required to confirm this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15465801     DOI: 10.1093/jn/134.10.2858s

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  8 in total

Review 1.  Supplements with purported effects on muscle mass and strength.

Authors:  Pedro L Valenzuela; Javier S Morales; Enzo Emanuele; Helios Pareja-Galeano; Alejandro Lucia
Journal:  Eur J Nutr       Date:  2019-01-02       Impact factor: 5.614

2.  Ornithine alpha-ketoglutarate: could it be a new therapeutic option for sarcopenia?

Authors:  S Walrand
Journal:  J Nutr Health Aging       Date:  2010-08       Impact factor: 4.075

Review 3.  Advances and challenges in the treatment of branched-chain amino/keto acid metabolic defects.

Authors:  Ina Knerr; Natalie Weinhold; Jerry Vockley; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2011-02-03       Impact factor: 4.982

4.  Current nutritional recommendations and novel dietary strategies to manage sarcopenia.

Authors:  Riccardo Calvani; Alfredo Miccheli; Francesco Landi; Maurizio Bossola; Matteo Cesari; Christiaan Leeuwenburgh; Cornel C Sieber; Roberto Bernabei; Emanuele Marzetti
Journal:  J Frailty Aging       Date:  2013

5.  Effect of ornithine alpha-ketoglutarate on glutamine pools in burn injury: evidence of component interaction.

Authors:  L Cynober; E Lasnier; J Le Boucher; A Jardel; C Coudray-Lucas
Journal:  Intensive Care Med       Date:  2007-01-18       Impact factor: 17.440

Review 6.  Alpha-Ketoglutarate: Physiological Functions and Applications.

Authors:  Nan Wu; Mingyao Yang; Uma Gaur; Huailiang Xu; Yongfang Yao; Diyan Li
Journal:  Biomol Ther (Seoul)       Date:  2016-01-01       Impact factor: 4.634

Review 7.  Alpha-Ketoglutarate as a Molecule with Pleiotropic Activity: Well-Known and Novel Possibilities of Therapeutic Use.

Authors:  Barbara Zdzisińska; Aleksandra Żurek; Martyna Kandefer-Szerszeń
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2016-06-20       Impact factor: 4.291

Review 8.  Efficacy of Nutritional Interventions as Stand-Alone or Synergistic Treatments with Exercise for the Management of Sarcopenia.

Authors:  Sarah Damanti; Domenico Azzolino; Carlotta Roncaglione; Beatrice Arosio; Paolo Rossi; Matteo Cesari
Journal:  Nutrients       Date:  2019-08-23       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.